Stents Bioresorbable

This channel includes news and new technology innovations for bioresorbable stents (BRS). These devices are also referred to as bioabsorbable stents, bioresorbable scaffolds and dissolving stents. BRS are designed as an alternative to permanent metallic stent implants, which cause issues in a small number of patients with in-stent restenosis, late-stent thrombosis and require use of long-term antiplatelet therapy. Metallic stents also cause issues with CT and MRI imaging and may prevent future options for coronary bypass graft (CABG) surgery. BRS are supposed to remove avoid these issues by dissolving and disappearing from the vessel after a period of 2-4 years. This, returns the vessel to its natural state and allows for the return of vasodilatation and vasoconstriction. BRS have had some issues in clinical trials not being able to match the performance of standard metallic drug eluting stents (DES) because of their thick stent struts. Newer generation BRS are in development with struts smaller than 100 micros, with will be closer to those of current generation metallic stents

 

A peripheral artery disease (PAD) patient CT scan showing blockages in the femoral arteries in the legs with collateral flow in the leg on the right.

A peripheral artery disease (PAD) patient CT scan showing blockages in the femoral arteries in the legs with collateral flow in the leg on the right.

News | Stents Bioresorbable | December 16, 2020
December 16, 2020 — Efemoral Medical announced the first-in-human (FIH) use of the its Efemoral bioresorbable vascular...
One-year results off the PIONEER III study comparing the safety and efficacy of the Supreme HT drug-eluting stent (DES), to the Xience or Promus Durable Polymer DES showed it was equivalent in clinical performance to the market-leading DES. The results were presented at the 2020 American Heart Association (AHA) Scientific Session. #AHA2020 #AHA20 #AHA

One-year results off the PIONEER III study comparing the safety and efficacy of the Supreme HT drug-eluting stent (DES), to the Xience or Promus Durable Polymer DES showed it was equivalent in clinical performance to the market-leading DES. The results were presented at the 2020 American Heart Association (AHA) Scientific Session.

News | Stents | November 24, 2020
November 24, 2020 — One-year results off the PIONEER III study comparing the safety and efficacy of the Supreme HT (...
Some of the device technologies discussed in the TCT 2020 late-breaking trial sessions. Top left, the  Medtronic Resolute Onyx stent was the first stent to receive FDA clearance for short duration dual-antiplatelet therapy, which was a big topic and subject of several sessions. Lower left, the Keystone TriGuard 3 TAVR embolic protection device did not demonstrate superiority over TAVR without use of embolic protection. Top right, the Abbott MitraClip. Acurate neo TAVR valve. #TCTconnect #TCT2020

Some of the device technologies discussed in the TCT 2020 late-breaking trial sessions. Top left, the Medtronic Resolute Onyx stent was the first stent to receive FDA clearance for short duration dual-antiplatelet therapy, which was a big topic and subject of several sessions. Lower left, the Keystone TriGuard 3 TAVR embolic protection device did not demonstrate superiority over TAVR without use of embolic protection. Top right, the Abbott MitraClip was the subject of two studies, including use to aid heart transplant patients. Bottom right, the Boston Scientific Acurate neo TAVR valve performed below the Sapien 3 and CoreValve Evolut.

Feature | TCT | October 29, 2020 | Dave Fornell, Editor
Here are some of the key takeaways from the late-breaking interventional cardiology and structural heart trials...
Videos | Cath Lab | October 17, 2020
Gregg Stone, M.D., presents the results of the PROSPECT ABSORB Trial in a press conference at the 2020 Transcatheter...
Abbott Espirit BTK Bioresorbable stent, or bioresorbable vascular scaffold (BVS) measures 99 microns and is made from poly-L-lactide (PLLA), a semi-crystalline bioresorbable polymer engineered to resist vessel recoil and provide a platform for drug delivery. Abbott Absorb

Abbott Espirit BTK Bioresorbable stent, or bioresorbable vascular scaffold (BVS) measures 99 microns and is made from poly-L-lactide (PLLA), a semi-crystalline bioresorbable polymer engineered to resist vessel recoil and provide a platform for drug delivery.

Feature | Stents Bioresorbable | September 03, 2020
September 3, 2020 — Abbott today announced the start of the LIFE-BTK clinical trial to evaluate the safety and...
The Boston Scientific Eluvia self-expanding, drug-eluting, peripheral stent.

The Boston Scientific Eluvia self-expanding, drug-eluting, peripheral stent.

Feature | Stents | February 11, 2020 | Saloni Walimbe
Cardiovascular diseases (CVDs) are among the leading causes of death across the globe. For patients suffering from high...
 Bioresorbable stent Abbott Absorb stent
News | November 08, 2019
November 8, 2019 — The Absorb bioresorbable stent (BVS) demonstrated good patency and clinical outcomes in patients...
News | Stents Bioresorbable | November 07, 2019
November 7, 2019 — Although the Abbott Absorb fully bioresorbable drug-eluting stent (DES) was taken off the market due...
Global Cardiovascular Stent Market Poised for Almost 7 Percent Growth Through 2025
News | Stents | August 21, 2019
August 21, 2019 — Increasing incidence of cardiovascular diseases worldwide is creating growth opportunities for the...
The cardiovascular innovation cycle presented by TCT Course Director Martin Leon, M.D. at TCT 2018. #TCT2018 #TCT #TCT18

The cardiovascular innovation cycle, presented by TCT Course Director Martin Leon, M.D., at TCT 2018.

Blog | Cath Lab | October 16, 2018
There is a hype cycle surrounding new technologies in all industries, but medicine is unique because of its focus on...
Bioresorbable stents (BRS) in development presented by Gregg Stone, M.D., during TCT 2017. Several of the players listed on the slider put their BRS development programs on hold after the negative data from the ABSORB III Trial, but a handful of smaller companies are still pushing the technology forward. #TCT #TCT2018

Bioresorbable stents (BRS) in development, presented by Gregg Stone, M.D., during TCT 2017. Several of the players listed on the slider put their BRS development programs on hold after the negative data from the ABSORB III Trial, but a handful of smaller companies are still pushing the technology forward. (Pghoto by Dave Fornell)

Feature | Stents Bioresorbable | October 12, 2018 | Dave Fornell, Editor
Bioresorbable stent (BRS) technology is not dead, but the unbridled enthusiasm seen two years ago for the technology...
A comparison of target lesion failure (TLF) of the Reva bioresorbable stent to the Absorb and top performing metallic DES. #TCT #TCT2018 #TCT18 #BRS #bioresorbablestents #bioresorbablescaffolds

A comparison of target lesion failure (TLF) of the Reva bioresorbable stent to the Absorb and top performing metallic DES. 

News | Stents Bioresorbable | October 12, 2018
October 12, 2018 – Reva Medical presented four key data sets demonstrating the capabilities of the company’s Fantom...
Videos | October 11, 2018
A discussion with Professor Ian Meredith, MBBS, Ph.D., global chief medical officer and executive vice president,...
Videos | TCT | October 03, 2018
DAIC Editor Dave Fornell takes a tour of some of the most innovative new cardiovascular technology he found on the expo...
Magnitude Bioresorbable Scaffold Shows Low MACE, Restenosis Rates at Nine Months
News | Stents Bioresorbable | October 01, 2018
October 1, 2018 — New results from the RENASCENT studies presented at the Transcatheter Cardiovascular Therapeutics (...